Manuela Latorre

ORCID: 0000-0002-0158-2722
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Asthma and respiratory diseases
  • Respiratory and Cough-Related Research
  • Allergic Rhinitis and Sensitization
  • Chronic Obstructive Pulmonary Disease (COPD) Research
  • Vasculitis and related conditions
  • Inhalation and Respiratory Drug Delivery
  • Eosinophilic Disorders and Syndromes
  • Eosinophilic Esophagitis
  • Sinusitis and nasal conditions
  • Pediatric health and respiratory diseases
  • Urticaria and Related Conditions
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Otitis Media and Relapsing Polychondritis
  • Cystic Fibrosis Research Advances
  • Systemic Sclerosis and Related Diseases
  • Respiratory Support and Mechanisms
  • Neonatal Respiratory Health Research
  • Occupational exposure and asthma
  • IL-33, ST2, and ILC Pathways
  • Contact Dermatitis and Allergies
  • Health Systems, Economic Evaluations, Quality of Life
  • Drug-Induced Adverse Reactions
  • Pharmaceutical studies and practices
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Chronic Disease Management Strategies

Nuovo Ospedale di Prato
2019-2024

University of Pisa
2012-2021

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2020

Lombardia Informatica (Italy)
2019

University of Palermo
2019

Mylan (Switzerland)
2019

Azienda Ospedaliera Universitaria Pisana
2015-2018

Czech Academy of Sciences, Institute of Physiology
2018

Istituto di Fisiologia Clinica
2018

Ospedale Cisanello
2016

BackgroundAsthma is one of the most common non-communicable respiratory diseases, affecting about 6% general population. Severe asthma, even if afflicts a minority asthmatics, drives majority costs disease. The aim this study to create pharmacoeconomic model predict corticosteroid-related adverse events in severe asthmatics and applying it first published epidemiologic data from Asthma Network Italy (SANI) registry.MethodsThe analysis was conducted perspective Italian National Healthcare...

10.1016/j.waojou.2018.12.001 article EN cc-by-nc-nd World Allergy Organization Journal 2019-01-01

Background: Benralizumab has been shown to restore good control of severe eosinophilic asthma (SEA). Robust data on benralizumab effectiveness over periods longer than 2 years are scarce. Methods: This retrospective multicentric study was conducted 108 Italian SEA patients treated with for up 36 months. Partial and complete clinical remission (CR) were assessed. Data analyzed descriptive statistics or using linear, logistic, negative binomial mixed-effect regression models. Results: At...

10.3390/jcm13103013 article EN Journal of Clinical Medicine 2024-05-20

Background. Neutrophilic bronchial inflammation is a main feature of bronchiectasis, but not much known about its relationship with other disease features. Aim. To compare airway inflammatory markers clinical and functional findings in subjects stable noncystic fibrosis bronchiectasis (NCFB). Methods. 152 NFCB patients (62.6 years; females: 57.2%) underwent cross-sectional evaluation, including microbiologic cell profile sputum, exhaled breath condensate malondialdehyde (EBC-MDA). severity...

10.1155/2015/642503 article EN cc-by Mediators of Inflammation 2015-01-01

Abstract Background The Italian severe/uncontrolled asthma ( SUA ) web‐based registry encompasses demographic, clinical, functional, and inflammatory data; it aims to raise awareness, identifying specific phenotypes promoting optimal care. Methods Four hundred ninety three adult patients from 27 centers (recruited in 2011‐2014) were analyzed. Results Mean age was 53.8 years. more frequently female (60.6%), with allergic (83.1%). About 30% showed late onset of diagnosis/symptoms (>40...

10.1111/all.13342 article EN Allergy 2017-10-26

Purpose: After adolescence, asthma is more frequent in females than males due to different hormonal, immunologic, and occupational/environmental factors.The higher prevalence severity of the disease have already been reported international registries.The aim this study was explore difference terms clinical, functional, biological characteristics between male female patients with severe a reallife, registry-based setting.Methods: Baseline data from Severe Asthma Network Italy registry were...

10.4168/aair.2021.13.2.219 article EN Allergy Asthma and Immunology Research 2021-01-01

Objective To evaluate the potential determinants of forced expiratory volume in 1 s (FEV1) decline workers with occupational asthma (OA) still exposed to causative agent. We hypothesised that sputum eosinophilia might be a predictor poor outcome after diagnosis. Setting, design and participants In specialistic clinical centre University Hospital Pisa, we studied 39 (28 M, 11 F) diagnosed as having OA, routinely followed up between 1990 2009. They were subgroup 94 affected by OA period: 9 had...

10.1136/bmjopen-2014-005748 article EN cc-by-nc BMJ Open 2015-01-01

Eosinophilic granulomatosis with polyangiitis (EGPA) is a necrotizing vasculitis that predominantly affects small- to medium-sized vessels. It characterized by wide spectrum of extrapulmonary symptoms, including sinonasal and paranasal sinus abnormalities. These are the most common features this disease, constituting diagnostic criteria for EGPA. However, actual clinical features, cellular mechanisms impact on patients' quality life (QoL) still matter study.Thirty-nine EGPA patients...

10.1159/000484602 article EN International Archives of Allergy and Immunology 2018-01-01

Background: Severe eosinophilic asthma (SEA) represents a substantial global health burden. Benralizumab has been shown to restore good control of asthma. Robust data on benralizumab effectiveness over periods longer than 2 years are still scarce. Methods: This retrospective multicentric study was conducted 108 Italian SEA patients treated with for up 36 months. Clinical outcomes were evaluated at 6, 12, 24 and Partial complete clinical remission (CR) also assessed. Data analysed either...

10.20944/preprints202402.1390.v1 preprint EN 2024-02-23

In the field of severe asthma, concept disease control has recently been integrated by one clinical remission. With this new concept, we move on to analyze efficacy therapy multiple parameters simultaneously, starting with mandatory discontinuation systemic glucocorticoids, which is added effect exacerbations, respiratory function, and symptoms control. The Italian asthma registry SANI (Severe Asthma Network Italy) drafted criteria for definition remission, allowing patients be classified...

10.1080/02770903.2024.2376919 article EN cc-by Journal of Asthma 2024-07-10

According to ATS/ERS document on severe asthma (SA), the management of these patients requires identification and proper treatment comorbidities, which can influence control asthma.The aim this study was assess independent effect different comorbidities clinical, functional biologic features SA. Seventy-two with SA according GINA guidelines were examined. We collected demographic data, smoking habit, history, assessment comorbidities. Pulmonary function, inflammatory biomarkers, upper airway...

10.1186/s12948-018-0103-x article EN cc-by Clinical and Molecular Allergy 2018-11-28

Objectives/Hypothesis To evaluate the clinical features of audiologic impairment and its relationship with nasal, vestibular, rheumatologic profile in a cohort patients eosinophilic granulomatosis polyangiitis (EGPA), formerly named Churg‐Strauss syndrome. Study Design Prospective cross‐sectional study. Methods Thirty‐nine EGPA, considered controlled according to Birmingham Vasculitis Activity Score Damage Index, underwent complete evalutaion otomicroscopy, impedance audiometry, speech...

10.1002/lary.25964 article EN The Laryngoscope 2016-04-14
Coming Soon ...